Patents by Inventor Rebecca Croasdale

Rebecca Croasdale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD3/BCMA/CD38 Trispecific Antibodies
    Publication number: 20240132615
    Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.
    Type: Application
    Filed: May 3, 2023
    Publication date: April 25, 2024
    Inventors: Maria PIHLGREN BOSCH, Mario PERRO, Olivia HALL, Laura CARRETERO IGLESIA, Adam DRAKE, Daniela PAIS, Rebecca CROASDALE-WOOD, Jérémy LOYAU, Carole ESTOPPEY, Ankita SRIVASTAVA, Michael DYSON, Julie MACOIN, Myriam CHIMEN, Thierry MONNEY, Cyrille DREYFUS
  • Bispecific HER2 antibodies and methods of use
    Patent number: 11787873
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES
    Publication number: 20230119537
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 20, 2023
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES
    Publication number: 20220275087
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: December 2, 2021
    Publication date: September 1, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • Protease-activated T cell bispecific molecules
    Patent number: 11242390
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Rebecca Croasdale-Wood, Christian Klein, Juergen Michael Schanzer, Kay-Gunnar Stubenrauch, Pablo Umana, Martina Geiger, Eric Sullivan, Jigar Patel
  • ACTIVATABLE BISPECIFIC ANTIBODIES
    Publication number: 20220017640
    Abstract: The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor- or inflammation-specific proteases, and the preparation and use of such bispecific antibodies.
    Type: Application
    Filed: November 6, 2020
    Publication date: January 20, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich BRINKMANN, Rebecca CROASDALE, Silke METZ, Juergen Michael SCHANZER, Claudio SUSTMANN, Pablo UMANA
  • BISPECIFIC HER2 ANTIBODIES AND METHODS OF USE
    Publication number: 20200291131
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: January 16, 2020
    Publication date: September 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Bispecific HER2 antibodies and methods of use
    Patent number: 10584178
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: March 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • TRIVALENT, BISPECIFIC ANTIBODIES
    Publication number: 20200062826
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: May 15, 2019
    Publication date: February 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich BRINKMANN, Rebecca CROASDALE, Eike HOFFMANN, Christian KLEIN, Ekkehard MOESSNER, Juergen Michael SCHANZER, Claudio SUSTMANN, Pablo UMANA
  • PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES
    Publication number: 20190119383
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: September 21, 2018
    Publication date: April 25, 2019
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • Bispecific antibodies
    Patent number: 10106600
    Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: October 23, 2018
    Assignee: Roche Glycart AG
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Harald Duerr, Christian Klein, Erhard Kopetzki, Wilma Lau, Joerg Thomas Regula, Juergen Michael Schanzer, Pablo Umana, Katharina Wartha
  • TRIVALENT, BISPECIFIC ANTIBODIES
    Publication number: 20180282399
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: December 28, 2017
    Publication date: October 4, 2018
    Inventors: Ulrich BRINKMANN, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
  • Trivalent, bispecific antibodies
    Patent number: 9890204
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
  • Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
    Patent number: 9574016
    Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: February 21, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Lau, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • BISPECIFIC HER2 ANTIBODIES AND METHODS OF USE
    Publication number: 20170029529
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: June 17, 2016
    Publication date: February 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale, Lydia Jasmin Duerner, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Multispecific antibodies comprising full length antibodies and single chain fab fragments
    Patent number: 9382323
    Abstract: The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: July 5, 2016
    Assignee: Roche Glycart AG
    Inventors: Ulrich Brinkmann, Peter Bruenker, Rebecca Croasdale, Christian Klein, Erhard Kopetzki, Ekkehard Moessner, Joerg Thomas Regula, Juergen Michael Schanzer, Jan Olaf Stracke, Pablo Umana
  • COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT
    Publication number: 20160009823
    Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: November 12, 2014
    Publication date: January 14, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • Bi-specific digoxigenin binding antibodies
    Patent number: 9050375
    Abstract: This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: June 9, 2015
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Birgit Bramlage, Ulrich Brinkmann, Rebecca Croasdale, Simone Dill, Wilma Dormeyer, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffmann, Ludger Markus Ickenstein, Kerstin Jahn-Hofmann, Matthias John, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • TRI- OR TETRASPECIFIC ANTIBODIES
    Publication number: 20150030598
    Abstract: The present invention relates to tri- or tetraspecific antibodies, their manufacture and use.
    Type: Application
    Filed: June 25, 2014
    Publication date: January 29, 2015
    Inventors: Rebecca CROASDALE, Christian KLEIN, Wolfgang SCHAEFER, Juergen Michael SCHANZER
  • Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
    Patent number: 8907069
    Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: December 9, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke